NDAORALTABLET
Approved
Feb 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
HIV Protease Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Clinical Trials (5)
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
Started Oct 2025
99,000 enrolled
COVID-19
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
Started Aug 2025
1,200 enrolled
Coronavirus Disease 2019 (COVID-19)
A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants
Started Aug 2025
0Biological AvailabilityHealthy Participants
A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
Started Nov 2023
8,252,912 enrolled
COVID-19
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Started Oct 2023
250 enrolled
Covid-19